Taking on board COVID-19 vaccine approval euphoria plus growth prospects
30/12/20 -"With UK’s emergency use approval for Astra-Oxford’s COVID-19 vaccine candidate, the sentiment around Astra’s share price should improve finally. Besides taking on board the 100% probability of ..."
Pages
65
Language
English
Published on
30/12/20
You may also be interested by these reports :
08/12/25
Despite US tariff threats, drug pricing pressures and the persistent insistence from the US government to reshore manufacturing, the AV Big Pharmas ...
05/12/25
Against the backdrop of strong execution, with two outlook upgrades in 2025, backed by vigorous growth across all its focus areas (oncology, ...
28/11/25
Novo’s investors losing more weight than its patients
25/11/25
CureVac’s Q3 sales surpassed market expectations, driven by a one-off contribution from GSK. The operating profit benefited from the resolution of ...